Boehringer Ingelheim Fremont, Inc.
About Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.
One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.
A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.
Biopharmaceuticals - Competence and Experience for Medicines of the Future Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
1014 articles about Boehringer Ingelheim Fremont, Inc.
-
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
-
More pharma workers in France are receiving coal in their stockings this year after Germany-based Boehringer Ingelheim announced plans to cut about 300 jobs in that country as part of a reorganization of its operations in France.
-
What’s Going on With the Biosimilar Market?
12/10/2018
Although a moderate presence in Europe, with about 25 biosimilars approved and on the market, they haven’t gained traction in the U.S. Even though at least 11 have been approved in the U.S., only about three are available, largely because of business tactics branded drug companies are using to sl... -
The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.
-
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
-
Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million up Front and $280 Millio...
11/15/2018
Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million. -
The U.S. Food and Drug Administration (FDA) gave the green light to Hyrimoz, a biosimilar to AbbVie’s blockbuster drug Humira, five years ahead of the time it can be launched in U.S. markets.
-
AbbVie’s Humira is the world’s best-selling drug that generated more than $18 billion for the Illinois-based company last year. This week though, the company will begin to see challenges to Humira in Europe from biosimilars developed by Amgen and Novartis, as well as others.
-
New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
10/10/2018
Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of Jardiance (empagliflozin) on life expectancy of adults with type 2 diabetes and cardiovascular disease
-
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
10/4/2018
All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment
-
Boehringer Ingelheim and Eli Lilly released data from their Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III trial in type 1 diabetes.
-
UPMC Health Plan and Boehringer Ingelheim Announce Innovative, Value-Based Agreement
9/27/2018
The UPMC Health Plan announced today the initiation of a value-based contract with Boehringer Ingelheim effective 1/1/2019 for Jardiance® (empagliflozin), an oral type 2 diabetes medicine also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
-
BioSpace Movers and Shakers Sept. 24
9/24/2018
Here's a look at who's making moves in the biotech and pharma world this week. -
AstraZeneca announced positive results from its Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
-
Boehringer Ingelheim announced earlier this week that Christopher Corsico was leaving the company, effective December 31. Today it was announced that Corsico will join GSK to take on the new role of senior vice president of development.
-
Boehringer Ingelheim Expands Oncolytic Virus Program and Buys ViraTherapeutics for $245 Million
9/13/2018
Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016. -
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
-
In May the U.S. Food and Drug Administration approved Amgen’s preventative migraine treatment Aimovig. Amgen and its developmental partner Novartis, said the medication would be ready within one week for patients.
-
Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval
8/28/2018
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).
-
Integra Connect Becomes CancerLinQ® Platform’s First Certified Electronic Health Record
8/28/2018
CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System.